In Pursuit of Disruptive
Anti-Ageing Drugs
Genflow Biosciences plc is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs.
The company’s lead compound operates through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results.
Led by a team boasting decades of experience in the pharmaceutical and biotechnology sectors, development programs are poised to sustain momentum over the next 24 months.
Transformative Medicine – Compassionate Medicine
Our ageing population represents one of the largest healthcare challenges facing the world today. From an ethical standpoint, ageing deserves the same attention and scientific pursuit as any other global health problem. Embracing this perspective opens avenues for advancing research and interventions that may not only extend lifespan but also enhance the quality of life throughout the ageing process.
Recent advances in biology suggest the ageing process can be influenced by more than just healthy lifestyle choices such as diet and exercise. Therapeutic interventions that can potentially slow down the ageing process hold immense promise for reaching old age as healthier and more active individuals.
Intellectually Curious
We view ageing as a complex process with the potential to be altered by therapeutics.
Collaborative
We have partnerships with highly experienced research centers and longevity funds.
Innovative
We employ the latest gene delivery techniques to safely introduce additional copies of the SIRT6 gene to regulate the ageing process.
Ethical
We conduct robust, high-quality preclinical research to support clinical testing.
Considerate
We are committed to reducing the economic and financial impact associated with an ageing population.
Courageous
Our goal is to be the first company to develop a disruptive anti-ageing drug through our leading compound GF-1002.
Rising Older Population
The United Nations predicts that the global population over the age of 65 will increase from 9.3% in 2020 to 22.6% by 2100. With an increasing number of individuals reaching their 80s, 90s, and beyond, and the baby boomers entering old age, the potential costs of an ageing society are well known, including rising health care costs amid shrinking government budgets.
Increased Health Expenditure
Due To Ageing
The OECD [1] estimates that health expenditure will rise from 8.8% of GDP in 2015 to 10.2% by 2030
The Economic Promise of Delayed Ageing
In the US where healthcare expenditure per capita is higher than any other country, the economic value of delaying biological aging ranges between $7-$38 trillion over 50 years.
[2] D. P. Goldman, D. Cutler, J. W. Rowe, P.-C. Michaud, J. Sullivan, D. Peneva, and S. J. Olshansky. Substantial Health And Economic Returns From Delayed Aging MayWarrant A New Focus For Medical. Research. Health A_airs (Millwood), 32(10):1698{1705, Oct. 2013. And A.J.Scott, M.Ellison and D.A.Sinclair “The Economic Value of Targeting Aging”, Nature Ageing, forthcoming.